China Lentinan Market, 2010-2019 - New Market Study Published

Currently, the incidence of malignant cancer is growing at 3%-5% with more and more younger people. The number of new cases of cancer exceeds 3 million each year with six confirmed cases every one minute. And bad living habits and changed environment have become the main risk factors of cancer.
Carbohydrate drug is the bioactive carbohydrate and its derivatives isolated from animals, plants, microbes and sea creatures. The diversity of carbohydrate structure determines the diversity of carbohydrate drug's bioactivity. One category of carbohydrate drugs is the immunoregulatory anti-tumor polysaccharide isolated from plants and microbes. Although chemotherapy drugs are the most common drugs for malignant cancer in the clinic, polysaccharide is with no side effects. Therefore, more and more polysaccharide drugs are used for the treatment or assistive treatment of tumor. Currently, fungi polysaccharide like lentinan, schizophyllan, ganoderan and pachymaran as well as higher plants polysaccharide such as astragalus polysaccharide and panaxan have been widely used in the clinic as immunomodulators and anti-tumor drugs.
As an intravenous biological response modifier, lentinan features potent antitumor effects, remarkably prolonged life, improved life quality and mild side effects. First developed by Japan, lentinan was approved to enter China in 1988. Although the practical use has confirmed lentinan's efficacy, its market size has been limited due to its high price.
After entering the 21st century, lentinan has become able to be produced domestically at a relatively low price. Therefore, its market size grows at an increasing rate, annual sales value rising from less than CNY 200 million in 2005 to CNY 473 million in 2014 and CAGR during this period reaching 11.3%. JinLing Pharmaceutical Co., Ltd FuZhou MeiFeng Factory, Chuang Li Yao Ye, Kanion Pharmaceutical, Nanjing Luye Sike Pharma Co., Ltd and Shanxi Zhendong Taisheng Pharmaceutical Co., Ltd occupy the majority of the Chinese market, among which JinLing Pharmaceutical Co., Ltd FuZhou MeiFeng Factory had the largest market share of about 39% for sales value in 2014.
With worsened environmental pollution and lifestyle change brought about by economic development, the incidence of cancer keeps growing. Therefore, the market size of lentinan in China is expected to grow too.

Full Report Details at
- http://www.fastmr.com/prod/1020585_china_lentinan_20102019.aspx?afid=301

Readers can get at least the following information from this report:

* market size of lentinan in China
* competitive landscape of lentinan in Chinese market
* price of lentinan made by different enterprises in China
* market outlook of lentinan in China

The author suggests the following groups of people purchase this report:

* manufacturers of immunomodulator
* manufacturers of antitumor drugs
* investors/ research institutions interested in Chinese medicine market

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156 (1.413.485.7001 Int'l)

You may also be interested in these related reports:

- Ajinomoto Pharmaceuticals Co., Ltd. - Pharmaceuticals & Healthcare - Deals and Alliances Profile
- Taiho Pharmaceutical Co., Ltd. - Pharmaceuticals & Healthcare - Deals and Alliances Profile
- Luye Pharma Group Ltd. (2186) - Pharmaceuticals & Healthcare - Deals and Alliances Profile